These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals]. Bret P; Bret MC; Queuille E Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic effects of butyrilperazine]. Bohacek N Neuropsihijatrija; 1964; 12(1-4):133-6. PubMed ID: 16305166 [No Abstract] [Full Text] [Related]
7. [Fatal poisoning with clozapine and perazine. A case report]. Ganssmann B; Skopp G; Aderjan R; Mattern R Arch Kriminol; 1998; 201(1-2):11-20. PubMed ID: 9541713 [TBL] [Abstract][Full Text] [Related]
8. [Physicians' opinion on the use of perazine in the treatment of mental disorders--results of the Delphi consensus study]. Adamowski T; Kiejna A Psychiatr Pol; 2012; 46(6):985-93. PubMed ID: 23479940 [TBL] [Abstract][Full Text] [Related]
9. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia. Woods SW; Gueorguieva RV; Baker CB; Makuch RW Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728 [TBL] [Abstract][Full Text] [Related]
10. Review of the evidence for the long-term efficacy of atypical antipsychotic agents in the treatment of patients with schizophrenia and related psychoses. Turner MS; Stewart DW J Psychopharmacol; 2006 Nov; 20(6 Suppl):20-37. PubMed ID: 17046985 [TBL] [Abstract][Full Text] [Related]
11. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness]. Wetzel H; von Bardeleben U; Holsboer F; Benkert O Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336 [TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for aggressive behaviours in persons with intellectual disabilities: treatment or mistreatment? Tsiouris JA J Intellect Disabil Res; 2010 Jan; 54(1):1-16. PubMed ID: 20122096 [TBL] [Abstract][Full Text] [Related]
13. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Kemmler G; Hummer M; Widschwendter C; Fleischhacker WW Arch Gen Psychiatry; 2005 Dec; 62(12):1305-12. PubMed ID: 16330718 [TBL] [Abstract][Full Text] [Related]
14. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Möller HJ Eur Arch Psychiatry Clin Neurosci; 2005 Dec; 255(6):371-2. PubMed ID: 16382376 [No Abstract] [Full Text] [Related]
15. Evaluating antipsychotic medications: predictors of clinical effectiveness. Report of an expert review panel on efficacy and effectiveness. Lalonde P Can J Psychiatry; 2003 Apr; 48(3 Suppl 1):3S-12S. PubMed ID: 12728783 [TBL] [Abstract][Full Text] [Related]
16. If 'atypical' neuroleptics did not exist, it wouldn't be necessary to invent them: perverse incentives in drug development, research, marketing and clinical practice. Charlton BG Med Hypotheses; 2005; 65(6):1005-9. PubMed ID: 16182461 [TBL] [Abstract][Full Text] [Related]